Skip to main content

Table 1 Particle size, PDI, zeta potential and EE of (A) NLC-Sal A/DOX, (B) FA-NLC-Sal A/DOX, (C) E-[c(RGDfK)2]-NLC-Sal A/DOX and (D) E-[c(RGDfK)2]/FA-NLC-Sal A/DOX

From: The anti-tumor and renoprotection study of E-[c(RGDfK)2]/folic acid co-modified nanostructured lipid carrier loaded with doxorubicin hydrochloride/salvianolic acid A

Items

A

B

C

D

Particle size (nm)

18.35 ± 0.21

17.23 ± 0.28

17.39 ± 0.36

18.15 ± 0.23

PDI

0.263 ± 0.035

0.209 ± 0.056

0.203 ± 0.035

0.212 ± 0.065

Zeta (mV)

− 4.32 ± 2.47

− 4.17 ± 1.83

− 4.82 ± 2.74

− 1.32 ± 1.26

Sal A

 EE (%)

82.83 ± 10.59

80.34 ± 6.24

81.87 ± 10.63

80.13 ± 8.59

DOX

 EE (%)

84.87 ± 8.68

79.96 ± 4.26

80.84 ± 7.94

80.36 ± 6.21

  1. Results are expressed as mean ± SD, n = 3